ANTX

Insider Trades

Name	Value	Action	Price	Current Price
Williams Sarah JoannePrincipal Accounting Officer $1.2k265 shares SellMay 29, 2026 $4.43 --
Williams Sarah JoannePrincipal Accounting Officer $347327 shares SellMar 3, 2026 $1.06 --

News

businesswire.comAN2 Therapeutics Reports Positive Enabling Data Supporting Advancement of Oral AN2-502998 to Phase 2 Study for Chronic Chagas Diseasebusinesswire.comJun 4

businesswire.comAN2 Therapeutics to Present at 2026 Jefferies Global Healthcare Conferencebusinesswire.comMay 21

businesswire.comAN2 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business and Scientific Highlightsbusinesswire.comMay 11

businesswire.comAN2 Therapeutics to Participate in 2026 Stifel Virtual Targeted Oncology Forumbusinesswire.comMay 7

businesswire.comAN2 Therapeutics Announces Initiation of Phase 2 Investigator-Initiated Clinical Trial of Epetraborole for Mycobacterium abscessus Complex Lung Diseasebusinesswire.comMar 31

Trade ANTX

About AN2 Therapeutics, Inc.

AN2 Therapeutics, Inc. is a biopharmaceutical company currently in its clinical development phase, specializing in the creation of treatments for uncommon, long-term, and severe infectious conditions. A key focus of their pipeline is epetraborole, an investigational oral medication designed for once-daily administration to individuals battling chronic non-tuberculous mycobacterial lung disease. This enterprise was established in 2017 and operates from its headquarters situated in Menlo Park, California.

CEO: Eric E. Easom
IPO Date: Mar 25, 2022

Market Data

Open: $3.81
High: $4.00
Low: $3.70
Volume: 166.9K
52W High: $6.91
52W Low: $1.00

Valuation

Market Cap: $107M
Enterprise Value: $54M

Financials

Free Cash Flow: $-30M
Revenue: $0
Net Income: $-35M
Cash: $20M
Debt: $0

Events

EarningsAug 11

EPS est. -0.23